Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8579384 | 0.87 | TAAR1 (0.48) | SMN1; SMN2TAAR1HSD17B10ALDH1A1CASP1 | |
| SCHEMBL10137832 | 0.87 | TAAR1 (0.51) | GAARAB9ASMN1; SMN2TAAR1HSD17B10 | |
| SCHEMBL10174302 | 0.86 | TAAR1 (0.50) | GAARAB9ASMN1; SMN2TAAR1HSD17B10 | |
| SCHEMBL12172855 | 0.83 | RAB9A (0.44) | GAARAB9ASMN1; SMN2TAAR1HSD17B10 | |
| SCHEMBL27000233 | 0.81 | GRM4 (0.56) | SMN1; SMN2TAAR1HSD17B10ALDH1A1CASP1 | |
| SCHEMBL24259751 | 0.81 | HSD17B10 (0.47) | GAARAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL12384303 | 0.79 | HSD17B10 (0.62) | GAARAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL26210903 | 0.78 | TAAR1 (0.46) | SMN1; SMN2TAAR1HSD17B10ALDH1A1CASP1 | |
| SCHEMBL20287581 | 0.77 | GAA (0.42) | GAARAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL20286452 | 0.77 | GAA (0.42) | GAARAB9ASMN1; SMN2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | GAA 27/4885RAB9A 2346/4885SMN1; SMN2 2633/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | GAA 27/4885RAB9A 2346/4885SMN1; SMN2 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.